论文部分内容阅读
目的评价头孢噻利和其他抗菌药物对临床常见革兰阴性、阳性菌的体外抗菌活性。方法收集2008年15所教学医院收集的849株非重复的临床分离菌株。菌株经中心实验室复核后,采用琼脂稀释法测定头孢噻利等抗菌药物的最低抑菌浓度(MICs)。结果非产ESBLs的大肠埃希菌、肺炎克雷伯菌、奇异变形杆菌以及弗劳地柠檬酸杆菌、产气肠杆菌、阴沟肠杆菌、黏质沙雷菌、普通变形杆菌对头孢噻利的敏感率为62.9%～100%,头孢噻利对这些菌的MIC50为0.016～4 mg/L;产ES-BLs的大肠埃希菌、肺炎克雷伯菌、奇异变形杆菌对头孢噻利的敏感率为32.4%～54.5%,头孢噻利对这些菌的MIC50为8～32 mg/L。鲍曼不动杆菌对头孢噻利的敏感率为54.5%,本品对其的MIC50为4 mg/L,铜绿假单胞菌对本品的敏感率为45.5%,本品对其MIC50为16 mg/L,嗜麦芽窄食单胞菌和洋葱伯克霍尔德菌对本品的敏感性较差。MSSA对头孢噻利的敏感率为100%,本品对其的MIC50为1 mg/L,MRSA对本品的敏感率为17.1%,本品的MIC50为16 mg/L。PSSP、PISP和PRSP对本品的敏感率分别为87.2%、40.5%和51.6%,该药对上述菌株的MIC50分别为0.016、4和1 mg/L,优于头孢吡肟。结论头孢噻利对大部分肠杆菌科细菌保持很高的体外抗菌活性,优于头孢曲松和头孢噻肟。头孢噻利对革兰阳性球菌的体外抗菌活性优于头孢吡肟。
Objective To evaluate the antibacterial activity of ceftibrin and other antibacterial agents in vitro against common Gram-negative and -positive bacteria in clinic. Methods A total of 849 non-repetitive clinical isolates collected in 15 teaching hospitals in 2008 were collected. Strains after central laboratory review, the use of agar dilution method for the determination of antibacterial cefoselir such as the minimum inhibitory concentration (MICs). Results Non-ESBLs-producing Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Citrobacter freundii, Enterobacter aerogenes, Enterobacter cloacae, Serratia marcescens, and Proteus vulgaris to ceftibride The susceptibility rate was 62.9% ~ 100%. The MIC50 of cefosipir on these bacteria was 0.016 ~ 4 mg / L. Escherichia coli producing ES-BLs, Klebsiella pneumoniae and Proteus mirabilis were sensitive to ceftazidime The rates ranged from 32.4% to 54.5%. The MIC50 of ceftibrin for these bacteria ranged from 8 to 32 mg / L. Acinetobacter baumannii sensitive to ceftizil 54.5%, the product of its MIC50 is 4 mg / L, Pseudomonas aeruginosa sensitivity of this product was 45.5%, the product of its MIC50 is 16 mg / L, Stenotrophomonas maltophilia and Burkholderia cepacia on this product is less sensitive. The sensitive rate of MSSA to ceftizuride is 100%, the MIC50 of this product is 1 mg / L, the sensitivity rate of MRSA to this product is 17.1%, and the MIC50 of this product is 16 mg / L. The sensitivity rates of PSSP, PISP and PRSP to this product were 87.2%, 40.5% and 51.6%, respectively. The MIC50 of this drug against these strains was 0.016, 4 and 1 mg / L respectively, which was better than that of cefepime. Conclusion Ceftibrin has high in vitro antibacterial activity against most Enterobacteriaceae bacteria, which is superior to ceftriaxone and cefotaxime. In vitro antibacterial activity of ceftibrin against Gram-positive cocci was better than that of cefepime.